Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced that its Phase 3 EASE LID clinical trial evaluating the company’s investigational compound ADS-5102 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments

Adamas Pharma (ADMS) Sees Red-to-Green MoveDecember 24, 2015 11:28 AM Adamas Pharmaceuticals (ADMS) PT Raised to $37 at Credit SuisseDecember 24, 2015 7:37 AM Adamas Pharma (ADMS) Ramps Into the CloseDecember 23, 2015 3:38 PM Adamas Pharmaceuticals (ADMS) PT Raised to $38 at Needham & CompanyDecember 23, 2015 2:18 PM Piper Jaffray Remains Bullish on Adamas Pharmaceuticals (ADMS)December 23, 2015 9:12 AM Adamas Announces Positive Top-Line Phase 3 Results of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson’s DiseaseDecember 23, 2015 6:00 AM